Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Metastasis - molecular studies and development of methods

4 publications found

Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ (2020)
MirGeneDB 2.0: the metazoan microRNA complement
Nucleic Acids Res, 48 (D1), D132-D141
DOI 10.1093/nar/gkz885, PubMed 31598695

Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ (2020)
MirGeneDB 2.0: the metazoan microRNA complement
Nucleic Acids Res, 48 (D1), D1172
DOI 10.1093/nar/gkz1016, PubMed 31642479

Møller P (2020)
The Prospective Lynch Syndrome Database reports enable evidence-based personal precision health care
Hered Cancer Clin Pract, 18, 6
DOI 10.1186/s13053-020-0138-0, PubMed 32190163

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 1-8 (in press)
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

 
Page visits: 347929